See the DrugPatentWatch profile for wegovy

Wegovy (semaglutide) is a medication used to treat obesity in adults with a body mass index (BMI) of 30 or higher, or with a BMI of 27 or higher who have at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol.

The recommended dosage of Wegovy is 2.4 milligrams (mg) subcutaneously (under the skin) once a week. The medication should be administered in the abdomen, thigh, or upper arm.

According to the prescribing information, Wegovy should be initiated at a dose of 0.4 mg subcutaneously once a week for one week, followed by a dose increase to 1.8 mg subcutaneously once a week for the next three weeks. After the initial 4-week titration period, the recommended dose is 2.4 mg subcutaneously once a week.

It is essential to note that Wegovy should only be used under the guidance of a healthcare provider and in combination with a reduced-calorie diet and increased physical activity. The medication should not be used as a substitute for a healthy lifestyle.

It is also important to monitor patients for signs and symptoms of pancreatitis, which is a potential risk associated with the use of Wegovy. Patients should be advised to seek medical attention immediately if they experience severe abdominal pain, nausea, vomiting, or diarrhea.

In conclusion, the recommended dosage of Wegovy is 2.4 mg subcutaneously once a week, with a titration period of 4 weeks. It is crucial to follow the recommended dosing regimen and to monitor patients for potential side effects.

Sources:

1. Wegovy Prescribing Information [1]
2. DrugPatentWatch.com - Semaglutide Patent Expiration [2]
3. National Institute of Diabetes and Digestive and Kidney Diseases - Obesity [3]

References:

[1] Novo Nordisk. (2020). Wegovy (semaglutide) injection, for subcutaneous use. Retrieved from <https://www.novonordisk.us/content/dam/forms/us/forms/wegovy/pi-wegovy.pdf>

[2] DrugPatentWatch.com. (n.d.). Semaglutide Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/semaglutide>

[3] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Obesity. Retrieved from <https://www.niddk.nih.gov/health-information/weight-management/obesity>